Navigation Links
Human Pheromone Sciences Voluntarily Files With SEC for Termination of Registration

SAN JOSE, Calif., March 30, 2012 /PRNewswire/ -- Human Pheromone Sciences, Inc. (EROX) ("HPS" or "the Company") filed a Form 15 with the SEC.  The Company filed a Form 15 with the SEC in order to effect a termination of registration of its common stock under the Securities Exchange Act of 1934.  Upon this voluntary filing the Company is no longer required to file periodic and current reports with the SEC, including Forms 10-K, 10-Q and 8-K.  The Company expects that its common stock will continue to be traded in the Pink Sheets under the symbol, EROX.

"The Company and its Board of Directors determined that this course of action would allow the Company to use its financial and management resources on operations rather than on regulatory compliance in a capital market which the Company is unable to benefit from until its financial position improves.  The Company will continue to license and supply new and existing customers with its three unique compounds currently available and focus energies on identifying research and development partners for additional compounds that have been identified," a spokesperson indicated. 

The Company is also announcing its unaudited results for the three months and the year ended December 31, 2011. For the three months ended December 31, 2011, net revenue was $146,000, representing a 35% decrease from revenues of $225,000 in the prior year period, and resulted  in net income of $12,000 ($0.00 per share) as compared with net income of $118,000 ($0.03 per share) for the three months ended December 31, 2010, a $106,000 decrease. For the year ending December 31, 2011, net revenues of $569,000, were 29% less than revenues of $806,000 generated in the year ended December 31, 2010. The net loss in the current year of $44,000 ($0.01 per share) was $53,000, or 55%, reduction from the $97,000 loss ($0.02 per share) recorded for the year ended December 31, 2010.

Revenues in 2011 were either flat or less than 2011 in each quarter and revenues by customer were all less than in 2010.  This decrease we attribute to the depressed global economic conditions and the lack of new product or product line expansions during the year, and an Asian customer converting to a non-exclusive license. The Company continued to reduce operating costs during 2011.  Administrative expense reductions of approximately $239,000 offset the gross profit decrease of $196,000 for the year resulting in a $53,0000 reduction to the a net loss of $97,000 for the year ended December 31, 2010 to $44,000 for the year ended December 31, 2011.

The Company has seen a renewed interest by existing customers, inquires from potential customers, and orders from new customers.  "We are pleased to see a renewed interest in the technology and continue to work in marketing the technology to consumer product companies that can incorporate our technology into their products," a spokesperson indicated.  The Company further noted that it continues to seek alternative distribution channels for its technologies and to generate marketing interest in its patent-pending sea coral based compound, classified as ER 303.

Human Pheromone Sciences, Inc. is a technology-based company, whose proof-of concept products included prestige-priced fragrances and toiletries and environmental products sold under the Natural Attraction®, REALM®, innerREALM® and  EROX® trademarks.  These products contain mood-enhancing compounds, whose efficacy has been validated at leading universities around the world, and whose use is covered under United States and foreign patents. The Company is also involved in research and product development efforts on new compounds that have been previously identified as stimulating the emotional centers of the human brain. Further information is available on line at follow



 HUMAN PHEROMONE SCIENCES, INC. Condensed Balance Sheets (Dollars in thousands)  December 31, December 31, 






AuditedAssetsCash and cash equivalents$


92Accounts receivable77




26Other current assets12


49Property and equipment, net-


- Total$





 Liabilities and Shareholders' Equity  Accounts payable$


42Other current liabilities142


102Deferred income - current33


146Deferred income – non-current30


24Common stock21,098


21,098Accumulated deficit(21,181)


(21,137) Total$





HUMAN PHEROMONE SCIENCES, INC.Condensed Statements of Operations (Dollars in thousands, except per-share data)  Three months Year ended December 31, ended December 31, 2011 2010 2011 2010 Unaudited Audited Unaudited Audited 







 Net revenues$




$   569


806Cost of goods sold9






128Research and development4






23Selling, general and administrative126













 Income (loss) from operations7













 Other income5












 Income (loss) before provision for  income taxes12













 Provision for Income taxes-












 Net income (loss)$













 Net income (loss) per share R  Basic$  0.00




$  (0.01)


$  (0.02)  Fully diluted$  0.00


$   0.02


$  (0.01)


$  (0.02) 







 Weighted average number of shares - Basic4,152






4,152Fully diluted4,922






4,152Net loss per share is based on the weighted average number of common shares and common equivalents outstanding during each period.  Certain common stock equivalents are excluded when their effect would be anti-dilutive. 


SOURCE Human Pheromone Sciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. First successful human results achieved: Implantable wireless microchip drug delivery device
2. Successful human tests for first wirelessly controlled drug-delivery chip
3. Foundation for Angelman Syndrome Therapeutics (FAST) Funds Human Clinical Trial
4. deCODE Genetics, in Collaboration with Academic Colleagues, Discovers Three Variants in the Sequence of the Human Genome that Affect the Risk of Thyroid Cancer
5. Cepheid Welcomes Senior Vice President of Human Resources
6. ReproCELL Licensed Commercialization Right on Human iPS Cell Derived Hepatocytes - Expected Launch in Q2 2012
7. AFFiRiS AG Invests Into Human Capital - Chief Business Officer Recruited
8. Singapore scientists lead human embryonic stem cell study
9. Roche NimbleGen and BGI Develop Advanced MHC Region Capture Technology for Human Disease and Biomedical Research
10. Integrated 3-D Imaging Facilitates Human Face Transplantation
11. Human Genome Sciences Europe Moves to the Cloud With Veeva CRM to Support New Lupus Treatment
Post Your Comments:
(Date:10/9/2015)... Oct. 9, 2015  Pulmatrix, Inc., (NASDAQ: PULM ) ... investor conferences. th Annual BIO Investor ... (2:00 pm EDT). --> th Annual ... am PDT (2:00 pm EDT). --> Pulmatrix ... Growth Stock Conference on Thursday, October 15, 2015 at 8:30 ...
(Date:10/8/2015)... 2015  Sorrento Therapeutics, Inc. (NASDAQ:  SRNE; Sorrento), ... cancer and associated pain, announced today that Dr. Henry Ji, ... at the Aegis Capital Corporation 2015 Growth Conference ... Corporation 2015 Growth ConferenceDate:Friday, October 9, 2015Time:10:00 to ... The Wynn in Las Vegas, NV , ...
(Date:10/8/2015)... , October 8, 2015 ... .   --> Goldman Small Cap ... the small cap and microcap sectors, announced today ... report on PharmaCyte Biotech, Inc. (OTCQB - PMCB), ... on developing and preparing treatments for cancer and ...
(Date:10/8/2015)... 8, 2015 /PRNewswire/ - RepliCel Life Sciences Inc. (OTCQB: REPCF) ... on the development of autologous cell therapies, today announced its ... taking place in the month of October: ... RepliCel will be presenting at the annual Partnering ... Mesa to be held October 7-9 in ...
Breaking Biology Technology:
... /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE YMI, TSX:YM), today announced that ... units at an issue price of US $1.20 for gross ... one common share and one half common share purchase warrant. Each whole ... until March 10, 2015 . , ...
... March 10 Bone Biologics, Inc. announced today ... shares from the Musculoskeletal Transplant Foundation (MTF). MTF now ... financing, MTF also provided a line of credit to ... by MTF that have allowed Bone Biologics, Inc. to ...
... ... ... ... ...
Cached Biology Technology:
(Date:9/28/2015)... 28, 2015 CLEAR, the leading ... expedited traveler service is coming to Austin-Bergstrom ... bringing a frictionless experience, serious speed and ... "CLEAR offers our travelers an expedited security ... Jim Smith , Executive Director, Austin-Bergstrom ...
(Date:9/28/2015)... JOSE, Calif. , Sept. 28, 2015 ... of human interface solutions, today announced that Lenovo has ... touch fingerprint sensor, FS4202, for its latest smartphone, the ... secure, password-free access to unlock the device and provide ... The feature-rich Natural ID FS4202 sensor ...
(Date:9/10/2015)... This report provides detailed descriptions of the sensor types ... types that will dominate in the future. Many product ... technology hype curve in the last five years before ... all of them is the prominence of sensor options ... Sensors collect data about the physical and chemical properties ...
Breaking Biology News(10 mins):
... Society today commends President Obama,s decision to sign a ... scientific evidence is used in the development of solutions ... memorandum rightly places science at the forefront of informing ... of solutions to issues such as enhancing energy security, ...
... of proteins, the molecular machines that drive all life, also ... study, in the journal Structure , reveals that after ... of innovation. The active regions of many proteins, called domains, ... host of structures that had never been seen before. This ...
... to treat critical limb ischemia in peripheral arterial ... thwarted by restenosis (the re-narrowing of the artery ... need for repeat treatments and the continued progression ... and amputation. Interventional radiologists have been studying a ...
Cached Biology News:
ma. plate stack height 70mm...
Rotor for four tube-loaded buckets; ma RCF 2550g; sold without buckets...
CQCS kit for etra KR 4i , (other units)....
A compact, high-speed single tube reader unit designed for benchtop 2D barcode reading. The unit can be used with all of ABgene's 2D barcoded tubes, including the 2ml CryoCode tube....
Biology Products: